Bumrungrad Hospital is a multi-specialty hospital that caters to patients’ needs across all medical specialties. As screening takes center stage in medicine, there is a clear need for technology-based tools to expedite various clinical processes in pre-test and post-test scenarios and especially empowering patients to understand their reports. In this age of information technology patients want the next level of digital experience and expect instant health information.

With HealthFAX™ as part of its clinical tools, Bumrungrad Hospital is providing seamless patient & clinician interactions, counseling, and support. This implementation includes consent, personalized risk assessment, pre/post-test education, and automated interactive return of results, all through intuitive online conversations. Patients may also ask questions to HealthFAX™ throughout the process and using AI-powered natural language processing HealthFAX™ responds with the info & resources they need. HealthFAX™ ExpertConnect empowers patients to connect with a health expert instantly if required.

Dr. Palita Lungchukiet, MD, CEO of the Bumrungrad Genomic Medicine Institute, remarked that, “We believed in the 4P-approach: predictive, preventive, personalized and participatory… in medical care. Genomic medicine helps with individual risk-assessment, which guides personalized preventive care as well as precise diagnoses and treatments. HealthFAX can assess whether patients would benefit from cancer genetic testing. Patients will be able to understand more about genetics and genetic testing through a friendly conversation. We believe that the integration of HealthFAX and one of the best-in-class healthcare providers, Bumrungrad, will keep patients in good health as long as possible.”

Dr. Gauri Naik, CEO of OptraHEALTH commented “We are super-excited to partner with Bumrungrad Hospital, a leading health system in Thailand. With growing traction for our innovative platform in North America and Europe, we are happy to make our products available for APAC customers. Using our patented technology, we aim to provide the best-in-class services clinical intelligence with HealthFAX™. We are proud to have a partner like Bumrungrad Hospital in Asia region to improve global healthcare through patient education and meaningful engagement.”

With an easy-to-use, automated approach, HealthFAX™ is helping both patients and clinicians from the initial appointment to results thereby delivering better healthcare and personalized treatment options. This also reduces the clinical workload on hospital staff enabling them to focus on important tasks.

Bionano Laboratories utilizes cutting-edge technologies to provide genetic diagnostics in both clinical and research settings. Bionano Laboratories intends to scale its operations while continuing to improve the customer testing experience by adopting the HealthFAX platform.

Within Bionano Laboratories’ new operational workflow, patients seeking additional information surrounding genetic disorders and testing services are sent a link to a custom HealthFAX virtual assistant through the program’s ExpertConnect™ feature. This feature provides information to patients on the genetic testing process and testing options and collects personal and family history needed for future potential discussions with genetic counselors. The approach will allow Bionano Laboratories to automate parts of their up-front education workflows and reduce the workload for their team, enabling Bionano Laboratories to potentially service greater numbers of patients while providing more efficient and effective customer care to their patients.

“We have chosen to incorporate the HealthFAX platform into the Bionano Laboratories workflow with the intent to increase operational efficiencies while also improving the overall experience for our clients,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano Laboratories’ parent company, Bionano Genomics. “With the implementation of these new tools, Bionano Laboratories will be able to scale as it expands services in the future.”

Dr. Gauri Naik, CEO of OptraHEALTH commented, “OptraHEALTH aims to make HealthFAX widely accessible to all families in need of more information about genetic testing for autism spectrum and other genetic disorders. It is unimaginable how much anxiety parents undergo while awaiting results for their child’s genetic test. The HealthFAX conversational platform will provide Bionano Laboratories with digital tools to better service their patient community while providing live support at scale as required.”

More information is available at: https://bionanolaboratories.com/

Approximately 10%-15% of all cancers are hereditary in origin and people with such genetic changes may go unnoticed until cancer manifests. siParadigm has several cancer panels for hereditary cancer testing, which are now accessible to everyone with HealthFAX™. The recent pandemic has proven that patients are tech-savvy and are comfortable using technology for their health goals.

HealthFAX™ gives siParadigm’s Neovare a new digital identity with its state-of-the-art technology and integration of HealthFAX™ in its business model. This means patients and providers have access to medical society guidelines and compliant, virtual assistants, 24*7, bringing scale into daily operations and removing process bottlenecks. siParadigm has already expanded into newer US territories as HealthFAX™ is empowering its sales teams to onboard new clinicians, healthcare systems and their patients.

Amy Halsted, Divisional Director at siParadigm said “This is a perfect example of technology meeting medicine! A tool like this is revolutionizing the patient identification process; a barrier which exists with the prevention and early detection of patients at a higher risk for developing a hereditary-based cancer in the future. This tool further allows the Oncology community to save time and capture relative patient information. This aids them in determining precision treatment options for their patients.”

“OptraHEALTH is excited to provide technological solutions to siParadigm for scaling their genetic testing services and efficiently managing their patients and providers. We are at an interesting time wherein an ever-increasing number of patients are seeking advanced genetic tests and HealthFAX™ is facilitating the entire testing process by providing conversational AI-powered virtual assistants that allow patients and providers to ask questions, perform risk assessments, and recommend tests.” said Dr. Naik Ph.D., CEO, OptraHEALTH.

siParadigm and OptraHEALTH together have identified and addressed the bottlenecks in the genetic testing process. With GeneFAX™, siParadigm’s Neovare is providing easy access to its genetic tests, ease of obtaining contextually relevant information, and making it simple for providers to order tests for their patients with read-to-sign requisitions, reports, and summaries.

The use of technology is inevitable in genetic testing given the increasing number of genetic tests and volume of data. OptraHEALTHs GeneFAX™ brings better engagement, experience, and conversationality to genetics at unprecedented levels. Beilinson Hospital will conduct a research study for its patients undergoing genetic counseling and education, an important aspect for patients to make informed decisions. As part of this study, Beilinson Hospital will send GeneFAX™ virtual assistants to patients and assess the quality, time, and scale of genetic counseling sessions using GeneFAX™. On this occasion, Prof. Lina Basel Salmon (Head of Department, Genetics Institute) from Beilinson Hospital said “Digital platforms assist in education of patients and help them to prepare for genetic counseling sessions. In addition, such tools facilitate the disclosure of testing results in a personalized and an understandable way.”

GeneFAX™ is a unique solution that enables any patient to conversationally obtain information. Dr. Ashwin Kotwaliwale MD Ph.D., Medical Director, OptraHEALTH said “GeneFAX™ is trusted by many large US labs, and we are excited to make GeneFAX™ available to our partners in Israel. GeneFAX™ empowers patients to make accurate health choices by providing a seamless experience.”

Gamidor Diagnostics is supporting the pilot in the region as the adoption of genetic testing services powered by technology is gaining wider adoption. Amichai Cnaan of Gamidor Diagnostics said, “We are excited to evaluate advanced digital genetic counseling tools with OptraHEALTH and our customers for a better patient’s treatment and accessibility to advanced preconception carrier screening and hereditary cancer testing.”

“Our advanced and patented AI technology coupled with Natera’s world-class clinical genetics testing solutions will empower Natera for their patient engagement related initiatives This endorses the power of our IP in the Healthcare segment”, said Dr Gauri Naik, Co-Founder & CEO, OptraHEALTH, Inc.

HealthFAX™ is brought to you by OptraHEALTH a world leader in genetic health ChatBot. The ChatBot is free to access.

“The COVID-19 pandemic has caused significant loss of life, chaos and panic. This is our contribution to support the community during this difficult time of global crisis. We have developed COVID-19 ChatBot to keep people informed and safe. We will continue to do everything we can to help protect the vulnerable and help end this pandemic.” said Dr. Gauri Naik, Co-Founder & Chief Executive Officer, OptraHEALTH.

OptraHealth’s AI framework has over 50,000 frequently asked questions about COVID-19. It has over 65 million ontologies to interpret the questions asked by patients using free text. Through this ChatBot, one can also live chat and live call with the physicians. OptraHealth's AI platform connects with organization’s EMR records, clinical notes and medical literature to derive meaningful insights during this pandemic using all the data points gathered conversationally through ChatBot.

AliveAndKickn develops educational programming for the Lynch syndrome community by providing information about the science, research, treatment, and care of Lynch patients and aims to take that to the next level with GeneFAX™. GeneFAX™ provides a transformative way in which individuals access information with the GeneFAX™ chatbot. Users can ask their questions about their condition, genes, treatment options, the risk to other family members, genetic testing, and more. GeneFAX™ understands the user's question by applying natural language understanding and enabling them to access accurate and up to date information quickly and easily.

“By implementing GeneFAX™ we have empowered AliveAndKickn to provide qualitative knowledge to individuals about Lynch Syndrome. Addressing the individual's concerns and reducing apprehension is our primary aim. GeneFAX™ is accessible globally and is always available. GeneFAX™ knowledgebase comprises more than 1M QAs allowing individuals to get any information about genetic health. instantly.,” said Dr. Ashwin Kotwaliwale, Medical Director at OptraHEALTH.

"Partnering with OptraHEALTH to bring the GeneFAX™ to those affected by Lynch syndrome enables us to further our mission to educate and support the community and help them manage their care," said Robin Dubin, Co-Founder and Executive Director of AliveAndKickn.

OptraHEALTH® has patented this invention which covers health information handling through the reporting system via the query-interrogation system. The knowledge-graphing system, which is generated using artificial intelligence modules, natural language understanding modules, and machine learning modules, is utilized to provide accurate information to the users. An administrative system monitors the validity of health information from these reporting systems.

"It’s a wonderful feeling to get the patent that describes our uniqueness in the AI-powered ChatBOT innovations for Healthcare Industry. With Patent and market leadership, we are now looking forward to making a significant impact in the healthcare market with the mission to augment the various processes in the healthcare and life science industry with intelligent, machine-assisted systems" said Dr. Gauri Naik, Co-Founder & CEO, OptraHEALTH, Inc.

“In this ever-changing society, the most powerful healthcare technologies are built passionately revolving around better patientcare.  We are delighted to announce our collaboration with Johns Hopkins University. GeneFAX™ advanced AI technology coupled with JHUs world-class clinicians and scientists will enable novel access to genetic education and appropriate genetic testing while maintaining patient satisfaction” said Dr. Gauri Naik, Co-Founder & CEO, OptraHEALTH, Inc.

Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer.

Gene will interactively engage individuals online, providing them with education about hereditary cancer prior to taking an online assessment to determine if they may be a candidate for genetic testing. Gene can also assist in finding a healthcare provider who can help a patient make an informed, definitive decision.

Gene interfaces with Myriad's market leading online hereditary cancer quiz, which is now taken by approximately one million people per year.

Myriad plans on launching the Gene chatbot for its Foresight and Prequel prenatal tests and for companion diagnostic testing in oncology later this calendar year.

The availability of GeneFAX™ Pro on Azure Marketplace will benefit genetic testing providers for their DTC as well as Diagnostics tests.

GeneFAX™ Pro is an AI-powered HIPAA compliant, knowledge platform for genetic health with BOT interfaces and has three modules: ChatBOT, KnowledgeBOT and QuizBOT. This new-gen AI platform is suitable for educating patients, qualifying their interest in various genetic tests, patient consenting, family triaging and pre-test counseling. “KnowledgeBOT” is a compilation of more than 450,000 Q&As pertaining to Genomics and Genetic Testing. GeneFAX™ has Natural Language Processing (NLP) framework to interpret and query GeneFAX™ knowledgebase using 65 million ontological records pertaining to diseases, drugs, biological entities, chemicals, clinical ontologies, etc. GeneFAX™ “QuizBOT” is one of the first AI tools to educate and assess pre-test readiness of any patient in compliance with ACOG, NCCN guidelines in a conversational way using Quiz format.

GeneFAX™ “CounselorConnect™” provides easy connectivity with 75+ telegenetic counselors to get questions answered in real-time. GeneFAX™ caters to a number of genetics panel such as Non-invasive Prenatal Testing (NIPT), Carrier Screening, Hereditary Cancer Screening, Newborn Screening, just to name a few. GeneFAX™ application’s presence in Azure Marketplace will allow customers to benefit from access to information of such genetics panel, for example, anytime and anywhere.

“There are more than 25 million genetic tests conducted every year – and that number is doubling yearly. While there are only 10 genetic counselors per million population. To avoid long waits to speak with human counselors, patients are turning to random online searches to get questions answered, which only results in more confusion for the obvious reasons. Physicians are also looking for ways to educate patients on appropriate genetic tests. OptraHEALTH has invented GeneFAX™ to address this dilemma for patients as well as physicians. We are proud to be a market leader for “AI in Genetic Health” and look forward to increasing our reach using Azure Marketplace”, said Dr. Gauri Naik, Founder & Chief Executive Officer, OptraHEALTH. “This collaboration will dramatically enhance our reach in conversational AI services offered in the genetic health industry,” she added further.

“Azure helps OptraHEALTH deliver solutions that enable customers to focus more on their patients and less on managing servers,” said David Houlding MSc CISSP CIPP, Director Healthcare Experiences, Cloud + AI at Microsoft Corp. “The GeneFAX™ solution addresses a variety of issues related to the healthcare industry and enables customers to take advantage of the flexibility and enterprise-grade reliability Azure provides.”

Azure Marketplace helps connect companies seeking innovative, cloud-based solutions with partners who have developed solutions that are ready to use. The availability of GeneFAX™ Pro on Azure Marketplace shall help customers to use genetic information on the go.

GeneFAX, a flagship product of OptraHEALTH, is an AI-powered knowledge platform for genetic health with bot interfaces. The GeneFAX™ platform includes a Digital Genetic Assistant trained on genetics knowledge to aid genetics labs/providers/payers in consenting, triaging, pre-test counseling and post-test counseling processes. GeneFAX™ Enterprise is a cloud service that empowers organizations to build and deploy, AI-powered virtual assistants and chatbots that can be used to enhance their processes, patient engagements and reduce costs.

InformedDNA was the first telegenetic service provider in the U.S. and now employs the nation’s largest, most experienced, full-time staff of genetic counselors. Covered specialties include: cancer, cardiac, neuro, ocular, reproductive, and pediatric genetics; pharmacogenomics; whole genome/exome sequencing; and, direct-to-consumer genetic test results consultation. Since InformedDNA is lab-independent, there are no conflicts of interest with its genetic counselors advising ordering providers and patients on the most appropriate use of genetic tests and their results.

GeneFAX CounselorConnect™ allows patients to schedule a genetic counseling appointment with a board-certified genetic counselor at their convenience. Patients may discuss about their families’ or their own genetic health and ask questions related to pre-test and post-test genetic testing, prenatal testing or any cancer-related genetic testing. GeneFAX’s CounselorConnect will enable GeneFAX™ users to access InformedDNA’s board-certified genetic counselors to connect remotely and obtain accurate answers to their questions and reach out to them for further steps on top of its AI powered e-counseling.

“We are committed towards providing accurate genetic information to the patients through GeneFAX™ and this partnership with InformedDNA will definitely help us in keeping our commitment. I strongly believe that the combination of GeneFAX’s AI technology and expert genetic counseling services of InformedDNA will extend the reach of genetic testing and engage users meaningfully”, said Dr. Gauri Naik, Founder & Chief Executive Officer, OptraHEALTH. She further added, “It will also empower users to get more out of genetic testing in order to take control of their health.”

To read the full coverage, please click link: https://www.bio-itworld.com/2019/11/08/optrahealth-informeddna-partner-to-expand-access-to-genetics-experts.html

San Jose, CA, March 30, 2020: OptraHEALTH^®, creators of GeneFAX™, the conversational AI platform trained on genetics and AdvaGenix, which provides advanced genetic testing for your family's diagnostic, reproductive, cancer, and proactive health care, announced today that Advagenix has implemented GeneFAX™ to assist their patients with accurate information about genetic health.

GeneFAX™, a flagship product of OptraHEALTH, is an AI-powered HIPAA compliant, knowledge platform for genetic health with BOT interfaces. By employing this AI-enabled technology BOT, AdvaGenix will collect information about their patients’ family history of cancer as well as understanding reproductive health issues. Patients will then get automatically directed to the right tests to AdvaGenix through GeneFAX™.

“There has been a heavy focus on enabling direct-to-consumer genetic testing over the last few years, but we cannot forget that most of this testing is still being ordered in a clinic. We want to make sure that physicians, genetic labs and patients are at the center of everything we develop,” said Dr. Gauri Naik, CoFounder & Chief Executive Officer, OptraHEALTH. “GeneFAX™, our quality-assured, HIPAA compliant knowledge platform will assist AdvaGenix to better engage with their patients for Hereditary Cancer & Reproductive Genetic Health diagnostic testing and promote their testing panels in appropriate healthcare settings.”, she further added.

The value of the GeneFAX™ platform is in the “layer” of AI technology that brings together the key components required to simplify patient screening and family history collection processes. These components include direct integrations into genetic testing laboratories, on-demand genetic counseling services, integrations into electronic health records, patient engagement tools, patient triaging tools, and digital representation of patient health data.

"Implementing machine learning techniques to tackle the vast amount of patient data that must be collected and analyzed helps cut down on costs for researchers and clinicians. Physicians are also looking for ways to educate patients on appropriate genetic tests. The techniques and platforms offered by GeneFAX™ are made available on AdvaGenix web portal that improves the efficiency of the clinical workflow process and enhances the accessibility of genomic information to individuals interested in learning more about how their genetic makeup may impact their health.," said Dr. William Kearns, President & Chief Scientific Officer, AdvaGenix.

San Jose, California-based Optra Health calls OptraGuru a "digital genetic assistant" that allows consumers and healthcare professionals alike to verbally query genetic data via Amazon Alexa and Microsoft's Cortana.

The OptraGuru system puts these consumer-grade digital assistants on the front end of iPhrenesis to help patients, genetic counselors, and bioinformaticians make sense of genetic test results — particularly those from direct-to-consumer testing companies Ancestry.com and 23andMe — in a conversational manner.

"One of the differences that we are trying to make in the industry is [in] how easily you can understand the genetic data and how can that be helpful to you," Optra Health Cofounder and Executive Chairman Abhi Gholap told GenomeWeb shortly after speaking at Health Level Seven International's annual Genomics Conference in Washington, DC.

There, Gholap gave the first public demonstration of the technology by speaking into an Alexa device attached to his laptop computer. The system seemed to work properly, explaining in lay terms the implications of specific gene variations from an Ancestry test.

Gholap said that there are "three clear applications" for OptraGuru: the direct-to-consumer tests; family genetic screening that might take place in a prenatal or neonatal environment; and tests ordered by clinicians in the context of diagnosing cancer or rare diseases. For now, though, Optra plans on concentrating on the first two.

"We have not gone much into the clinical test as such because we still [need to tune] our systems to that level," Gholap said. Plus, there are regulatory considerations for moving into the professional side of genomic interpretation.

Consumer genomics interests Optra because so many patients already struggle with basic health literacy, according to Gholap.

"We have chosen genomics as the field to begin with because I think there are more complexities," Gholap said.

"With genetic data, patients are becoming even more confused," he added. "What they are trying to understand from the [genetic] report is based on their own understanding of the medical sciences." That often is not very extensive.

"They will never be able to match the physician level" in terms of medical knowledge, Gholap said of typical consumers. But physicians — particularly those in primary care — often do not have the time during a patient visit to explain the health implications of a genetic test.

"That's why we were trying to build kind of a conduit where maybe the first level of questioning can be handled by the machine," Gholap said. In genetics and genomics, medical professionals often are asked many of the same questions repeatedly, and an automated database can take some of the pressure off them, he suggested.

Plus, the relatively young field of genomics is rapidly evolving and the body of knowledge is constantly changing. "Maybe there is a researcher in Spain who published something just a couple of hours back," Gholap said. "In our system, that is an advantage that you get. You are going to get very up-to-date information."

When Optra released its iPhronesis natural language processing app in March 2017, it only included a keyboard interface. But the company found that that strategy had limitations. "People feel more comfortable if they feel they are interacting with someone. That's where we extended to also interface with voice devices," Gholap said.

Instead of, for example, setting up a call center to augment the original system, Optra chose to leverage the voice-controlled smart speakers that are proliferating, in part because customer service representatives may not even be fully up to date, Gholap said.

Meanwhile, patients regularly search the internet to try to make sense of their test results. Google and other search engines, of course, do not always return trustworthy medical information, and even if they do, users do not always click on the most reliable sites.

"That's lacking the context," Gholap said. Some sound medical sites may be written in scientific rather than lay language, too, leaving patients with a partial understanding of their results.

"Half knowledge is always riskier," Gholap said. "You have to create a context, and that's why we created this."

Google ranks results by popularity, which is not necessarily the most medically relevant. Optra has about 75 different web crawlers in its Amazon Web Services cloud to look for and parse new, relevant information, according to Gholap. "Less human intervention is a key here," he said.

For quality control, Optra has a global team of about 40 geneticists to curate and verify data. The company has built an app for these professionals to notify them of new knowledge and give them a curation platform.

"They don't do every step of the curation," Gholap said. Some algorithms help weed out unreliable bits of information. The geneticists can choose to accept, reject, or modify reports that the app presents to them.

"Based on that algorithm, we are pulling the data, we are curating the data, we are parsing the data, we are verifying the data," Gholap said. Humans only have to intervene for quality control on some of the more technical points.

"Any information that has been given to any user [by OptraGuru] is not generally based on the number of hits or something, but is based on the relevance. It is something that we are parsing, so your answer becomes more contextual," Gholap said.

Gholap said that Optra is looking to interface the technology with additional digital assistants, including Google Assistant and Apple's Siri. "We would like to be agnostic of device commands," he said. With Siri, users would be able to tap into OptraGuru on their iPhones rather than needing an external device, he noted.

Optra, which has been working on its database of genomic knowledge for about two years, has some big names on its team. Scott Kahn, a former chief information officer of Illumina, serves as chief strategy advisor.

The chairman of Optra's science advisory board is Personal Genome Project founder and CRISPR pioneer George Church. "Dr. Church essentially brings this new concept to look at the [consumer] genomic data," Gholap said.

Patrick Soon-Shiong personally invested in Optra Health and became part of the company's board about a year ago. In 2016, Soon-Shiong's NantOmics invested in telepathology company OptraScan, a sister organization to Optra Health under the Optra Group umbrella.

Link: https://www.genomeweb.com/informatics/optra-health-launches-digital-genetic-assistant-explaining-genetic-tests

locked away in corporate and public data silos, combines it with leading edge artificial intelligence and conversational technologies like Amazon Alexa to give genetic testing organizations the ability to offer a ‘round-the-clock’ personalized and engaging service to their consumers, and more effective tools for their genetic counselors and scientists.

OptraHEALTH^® will be introducing OptraGURU at the HL7 Genomics Conference in Washington D.C. February 19 – 21 [st] , where Mr. Abhi Gholap, Co-founder and Executive Chairman, will be discussing ‘The Intersection of Artificial Intelligence and Healthcare as it relates to Innovation’.

OptraGuru™ Technology and Amazon Alexa

Consumers have more access to data than ever before which presents potential risks in interpreting complex and often ambiguous information. Genetic Counseling can clear up this ambiguity but may not be readily available when the consumer needs it. OptraGURU™, powered by Optra Health’s iPhronesis™ artificial intelligence platform and its advanced Natural Language Understanding (NLU), and Deep Machine Learning (ML) capabilities, combined with an extensive ontological library of over 65 million unique concepts, provides consumers the ability to access their personal genetic reports via their provider, simply by asking Alexa. Once accessed, using Amazon’s Voice Recognition (VR) and Natural Language Processing (NLP) capabilities, OptraGURU communicates the results in a comprehensive and compassionate manner. Consumers can engage in a conversation with OptraGURU; asking questions and getting detailed answers about their results.

OptraGuru is not limited to consumers—genetic testing organizations can deploy OptraGURU to their genetic counselors engaged in family screening, allowing them to access and compare reports across an entire family and keep up-to-speed with the latest research – ensuring counseling sessions can be more effective. Additionally, OptraGURU can be used by bioinformaticians and scientists involved in data analysis to conversationally interrogate raw data and gather more evidence prior to report generation.

"The convergence of artificial intelligence, conversational technologies like Alexa, and an ever-increasing availability of data is having a transformative effect on how research and clinical results are delivered and communicated,” said Co-founder and CEO Gauri Naik. “The possibilities of using OptraGURU and Ai platforms like iPhronesis™ in combination with extensive public and private data sets, will advance research and improve the consumer experience. We look forward to making OptraGURU accessible to genetic testing organizations that are interested in providing more value through a personalized, digital approach."

personalized and engaging service to their consumers, and more effective tools for their genetic counselors and scientists.

To read the full coverage, please click link:https://www.americanentrepreneurship.com/component/ri_announcement?view=announcementstartup&id=90

Biography: Gauri is a biotechnologist with an extensive commercial research and entrepreneurial background. Before founding Optra Systems, Inc., she was the founder and principal scientist at BioImagene Inc., a silicon valley based digital pathology company which was acquired by Roche Diagnostics. Gauri is responsible for enriching the domain knowledge of her companies, as well as involved in the strategic planning and business development activities. Gauri has extensive experience working in the genetics, cytology, microbiology, molecular biology, medical imaging and bioinformatics fields. Gauri was selected as a young scientist for various research programs in biotechnology and microbiology internationally. She has 11 U.S. patents published to her credit. She has published many research papers in international journals and has participated as a speaker in many international conferences. She is on the editorial and advisory boards of many prestigious journals and forums, including the Journal of Applied & Translational Genomics and the International Organization for Rare Genetic Disorders. Gauri was also awarded with the prestigious “Woman Entrepreneur Award" by the government of India.

Abstract: Healthcare and life sciences are generating BigData. Rising costs of healthcare has presented an opportunity for developing newer, robust healthcare models for efficient treatment, likelihood prediction such as patients presenting with vague symptoms, disease prevention by pre-clinical identification and personalized treatment options for patients. iPhronesis™ is an advanced BigData Analytics platform, built to address specific patient centric functions. iPhronesis™ delivers the true power of biomedical BigData by integrating disparate data sources such as EMR/ EHR/ genomics/ imaging/ scientific literature etc., both structured & unstructured, applying powerful analytics, some which are based on machine learning and Bio Natural Language Processing(Bio-NLP) tools enabling better understanding of data, discovering hidden relationships and presenting results with real evidences. iPhronesis™ allows users to choose from a series of domain specific workflows & processes, customizing each step, and integrating with custom algorithms. Every workflow is publishable as APIs or presented to the user interface. When data such as EMR/ EHR are combined with images or with genomics, it allows for generating patient longitudinal views, representing a complete patient/ cohort profile, identifying patterns, which help identify risk factors, predict disease progression, accurate disease classification and efficacy of treatment such as drug dose modification, adverse side effect identification and effects with comorbidity, to name a few. As a platform, iPhronesis™ also integrates with mobile applications increasing patient engagement, retention and enabling organizations to proactively reach a wider audience with analytics based evidences.

To read the full coverage, please click link:https://www.omicsonline.org/abstract/iphronesis-a-big-data-analytics-platform-for-personalized-precision-medicine/

In the backend, OptraGURU relies on Optra Health’s iPhronesis AI platform and its advanced Natural Language Understanding (NLU), and Deep Machine Learning (ML) capabilities, combined with an extensive ontological library of over 65 million unique concepts, to provide users with the ability to access their personal genetic reports via their provider, simply by asking Alexa. Once accessed, OptraGURU communicates the results in a comprehensive and compassionate manner. Consumers can also engage in a conversation with OptraGURU to get detailed answers about their results.

In addition to end-users, Optra Health is also targeting genetic testing organizations for its latest offering, enabling them to deploy OptraGURU to their genetic counselors engaged in family screening. This in turn allows counselors to access and compare reports across an entire family and keep up-to-speed with the latest research. Furthermore, OptraGURU can be used by bioinformaticians and scientists involved in data analysis to conversationally interrogate raw data and gather more evidence prior to report generation.

“The convergence of artificial intelligence, conversational technologies like Alexa, and an ever-increasing availability of data is having a transformative effect on how research and clinical results are delivered and communicated,” Optra Health Co-founder and CEO Gauri Naik said in a statement. “The possibilities of using OptraGURU and Ai platforms like iPhronesis in combination with extensive public and private data sets, will advance research and improve the consumer experience. We look forward to making OptraGURU accessible to genetic testing organizations that are interested in providing more value through a personalized, digital approach.”

To read the full coverage, please click link:https://mhealthspot.com/2018/02/alexapowered-optraguru-launches-conversational-digital-genetic-assistant/

Lorem ipsum

Lorem ipsum

Lorem ipsum

Our 3 trends converging here are:

Spit Stories (from Consumer Trends)

More accessible, affordable home test kits are driving a fast-growing number of people to trade a little saliva for a lot of knowledge.

Our heritage and health futures are only a spit away. Discreet home testing now provides consumers with tools to dive as deep into their results as they wish -- exploring their backgrounds, tracing their ancestors and even getting insight into their likelihood for future diagnoses.

Let’s Chat (from Digital Trends)

2017’s quick leap into voice navigation and chatbot-ing has set a new expectation that engagements with brands should be friendly, conversational, and often UI free.

The way we interact with content changed dramatically in 2017. Alexa and Google Home took voice navigation mainstream. Retailers around the world dove into AI-powered chat platforms. Everyone seemed to agree: It was a great year to start talking. In 2018, talk first will become the expectation.

Artificial Intelligence + Real Patients (from Digital Trends)

What’s wrong? In 2018, only the bots can tell you. Increasingly, the first interaction people will have with the healthcare system will be an AI diagnostic that routes them to just the right care.

Investors and healthcare professionals alike are incredibly bullish about the potential of artificial intelligence for triaging and even diagnosing health challenges. But to date, this is a conversation without a very critical voice— the patients’.

So how is Optra Health mixing-and-matching these three trends to perfection? In a nutshell, the new platform helps patients digest complicated genetic testing results by translating everything into conversational patient-friendly explanations. Once OptraGURU has been loaded onto an Echo or the like, users can simply ask Alexa to access their report and hear a summary in understandable language. They can even ask specific questions about their results to receive answers in real time and other personalized insights.

CEO and cofounder Gauri Naik recently stated, “The convergence of artificial intelligence, conversational technologies like Alexa, and an ever-increasing availability of data is having a transformative effect on how research and clinical results are delivered and communicated…The possibilities of using OptraGURU and AI platforms like iPhronesis, in combination with extensive public and private data sets, will advance research and improve the consumer experience.”

OptraGURU is clearly staged to bring value to patients, but physicians and genetic counselors stand to benefit as well. In light of research that suggests PCPs may not be adequately equipped to explain and leverage patients’ genetic information, the former may appreciate the translation and simplification it offer. The latter can use the platform to keep up with the latest genetic research as well as compare multiple reports at once to better understand data sourced from across a family.

Why This Matters—

While individual trends offer useful insight on their own, their greatest value often emerges when we see the complex interactivity as they intersect one another. Today technology, science and human insights are developing faster and faster every day—we are witnessing a super-convergence in healthcare, and thus should expect to see countless more examples like this in the coming year. The best will raise the bar for patients, HCPs and all of us.

To read the full coverage, please click link:https://syneoshealthcommunications.com/blog/ai-genetics-patients-win

Notably, the Gene knowledge platform, which is a Health Insurance Portability and Accountability Act compliant, has a BOT interface and can answer a variety of health-related questions about hereditary cancer. The ChatBOT interfaces with Myriad’s online hereditary cancer quiz.

Myriad Genetics is currently planning to launch the Gene ChatBOT for its Foresight and Prequel prenatal tests and for companion diagnostic testing in oncology in the latter half of 2020.

With the recent partnership, Myriad Genetics aims to boost its oncology portfolio on a global scale. This portfolio includes various molecular diagnostic tests, all of which comprise the broader Molecular Diagnostic Testing business.

More on Gene

The ChatBOT Gene is designed to automate a pre-test process for individuals meeting the criteria for further evaluation post a preliminary assessment. Gene can also assist in finding a healthcare provider who can help a patient make an informed and definitive decision on whether testing is appropriate and then order the same if required.

Significance of the Collaboration

Per management, the ChatBOT will enable the provision of improved pre-test education solutions, which can be supplemented with live sessions as per requirement. Myriad Genetics believes that implementing the AI-powered technology will provide patients a wider access to online genetic education and support tools.

The partnership is strategic given the ongoing pandemic-led situation where patients may prefer to defer their clinic visits. Under such circumstances, remote pre-test education is required to determine whether testing is appropriate for the patients. This can be solved by the ChatBOT.

Industry Prospects

Per a report by Grand View Research, the global molecular diagnostics market size was valued at $9.2 billion in 2019 and is anticipated to reach $18.2 billion by 2027, at a CAGR of 9%. Factors like technological advancements in molecular diagnostics and the growing prevalence of infectious diseases are expected to propel the market.

Given the market potential, the collaboration is expected to significantly boost the business.

Recent Developments in Molecular Diagnostics

Of late, Myriad Genetics has been witnessing a slew of developments.

The company launched a new patient home-collection kit for its GeneSight Psychotropic test in July. This enables the DNA sample collection that is generally undergone in a clinician’s office to be completed at home.

Myriad Genetics, in June, announced publication of a new study in Future Medicine which validates the accuracy of myPath Melanoma while classifying skin lesions termed as indeterminate by standard pathological reviews.

In May, the company received the FDA’s approval for its BRACAnalysis CDx test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer, who are eligible for treatment with Lynparza (olaparib).

Price Performance

Shares of the company have lost 16.8% in the past three months against the industry’s 17.4% growth and the S&P 500’s 16.1% rise.

Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer. Gene interfaces with Myriad’s market leading online hereditary cancer quiz, which is now taken by approximately one million people per year.

“We are excited to offer this innovative new tool for physicians and patients to provide best-in-class pre-test education solutions that we can supplement with live sessions when necessary,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Myriad is highly focused on making the screening and testing process as streamlined as possible for healthcare providers and the implementation of this new technology will give their patients access to unparalleled online genetic education and support tools. This is especially important in the current environment with COVID-19 where patients may not be returning to the clinic setting and pre-test education can be particularly helpful as they work remotely with the healthcare provider to determine if testing is right for them.”

Gene will interactively engage individuals online, providing them with education about hereditary cancer prior to taking an online assessment to determine if they may be a candidate for genetic testing. For those who complete the preliminary assessment and meet criteria for further evaluation, Gene will automate a pre-test process that sends an educational link that displays interactive multimedia content and gives the option to start a live conversation with a patient educator, who is a certified genetic counselor. Gene can also assist in finding a healthcare provider who can help a patient make an informed, definitive decision whether testing is appropriate and then order testing if so. Myriad plans on launching the Gene chatbot for its Foresight® and Prequel™ prenatal tests and for companion diagnostic testing in oncology later this calendar year.

Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer. Gene interfaces with Myriad’s market leading online hereditary cancer quiz, which is now taken by approximately one million people per year.

“We are excited to offer this innovative new tool for physicians and patients to provide best-in-class pre-test education solutions that we can supplement with live sessions when necessary,” said Nicole Lambert, president of Myriad International, Oncology and Women’s Health. “Myriad is highly focused on making the screening and testing process as streamlined as possible for healthcare providers and the implementation of this new technology will give their patients access to unparalleled online genetic education and support tools. This is especially important in the current environment with COVID-19 where patients may not be returning to the clinic setting and pre-test education can be particularly helpful as they work remotely with the healthcare provider to determine if testing is right for them.”

Gene will interactively engage individuals online, providing them with education about hereditary cancer prior to taking an online assessment to determine if they may be a candidate for genetic testing. For those who complete the preliminary assessment and meet criteria for further evaluation, Gene will automate a pre-test process that sends an educational link that displays interactive multimedia content and gives the option to start a live conversation with a patient educator, who is a certified genetic counselor. Gene can also assist in finding a healthcare provider who can help a patient make an informed, definitive decision whether testing is appropriate and then order testing if so. Myriad plans on launching the Gene chatbot for its Foresight® and Prequel™ prenatal tests and for companion diagnostic testing in oncology later this calendar year.

San Jose, CA, June 18, 2020: OptraHEALTH^®, a leading data-driven intelligence company, announced new features for its flagship product GeneFAX™: A Digital Navigator for Genetic Testing. GeneFAX™ is trained on Genetic Health empowering organizations to implement workflows for patient triage, pretest education, and post-test counseling and helping physicians recommend appropriate genetic tests.

In addition to already existing modules like ScreeningBOT, KnowledgeBOT, and PhysicianBOT, OptraHEALTHs GeneFAX™ team has just released the CascadeBOT and InsuranceBOT and starting now GeneFAX™ is also available on other social media apps.

Patients that undergo a triage for hereditary cancers or carrier screening and meet the criteria for genetic testing have a question in mind about family member testing. The newly added GeneFAX™ CascadeBOT module proactively allows the patient to inform relevant family members about the benefits of genetic testing. Such a coordinated effort at family genetic testing means fewer patients with diseases. GeneFAX™ CascadeBOT also provides regular notification to patients and their family members about their genetic health.

Genetic tests are increasingly accepted by health insurance plans and patients have questions about how the insurance system works for genetic testing. GeneFAX™ through its InsuranceBOT provides quick answers to such questions but also lets patients find the cost of the test, their eligibility to take the test, and collects data for prior authorization. Healthcare providers receive this complete data ready to send for prior authorization at the click of a button.

GeneFAX™ is now multichannel and all GeneFAX™ BOTs are available on WhatsApp®, this will provide the patient community access to GeneFAX™ from their social media app, too.

“With the addition of GeneFAX™ CascadeBOT and InsuranceBOT, GeneFAX™ provides a solution to all aspects of the genetic testing process, providing a seamless user experience while collecting data for insurance prior-authorization. Providers receive a fully completed dataset for prior authorization submission. And being able to submit it instantly is a big step forward. Organizations and patients are set to gain from reduced denials, thus truly making genetic testing available to everyone.” said Dr. Ashwin Kotwaliwale MD Ph.D., Medical Director, OptraHEALTH.

Using the same engine that drives GeneFAX™, OptraHEALTH recently also launched HealthFAX.AI™ for COVID-19 that includes an array of tools such as contact tracing, self-symptom checker, finding test centers, COVID-19 KnowledgeBOT, etc. Using HealthFAX COVID-19 patients can be assured of information about COVID-19 at their fingertips. The contact tracing module of HealthFAX.AI providers immediate real-time notifications if someone has come nearby of another person having COVID-19.

Lorem ipsum

Lorem ipsum

Lorem ipsum

GeneFAX™ Pro is an AI-powered HIPAA compliant, knowledge platform for genetic health with BOT interfaces and has three modules: ChatBOT, KnowledgeBOT and QuizBOT. This new-gen AI platform is suitable for educating patients, qualifying their interest in various genetic tests, patient consenting, family triaging and pre-test counseling. “KnowledgeBOT” is a compilation of more than 450,000 Q&As pertaining to Genomics and Genetic Testing. GeneFAX™ has Natural Language Processing (NLP) framework to interpret and query GeneFAX™ knowledgebase using 65 million ontological records pertaining to diseases, drugs, biological entities, chemicals, clinical ontologies, etc. GeneFAX™ “QuizBOT” is one of the first AI tools to educate and assess pre-test readiness of any patient in compliance with ACOG, NCCN guidelines in a conversational way using Quiz format.

GeneFAX™ “CounselorConnect™” provides easy connectivity with 75+ telegenetic counselors to get questions answered in real-time. GeneFAX™ caters to a number of genetics panel such as Non-invasive Prenatal Testing (NIPT), Carrier Screening, Hereditary Cancer Screening, Newborn Screening, just to name a few. GeneFAX™ application’s presence in Azure Marketplace will allow customers to benefit from access to information of such genetics panel, for example, anytime and anywhere.

“There are more than 25 million genetic tests conducted every year – and that number is doubling yearly. While there are only 10 genetic counselors per million population. To avoid long waits to speak with human counselors, patients are turning to random online searches to get questions answered, which only results in more confusion for the obvious reasons. Physicians are also looking for ways to educate patients on appropriate genetic tests. OptraHEALTH has invented GeneFAX™ to address this dilemma for patients as well as physicians. We are proud to be a market leader for “AI in Genetic Health” and look forward to increasing our reach using Azure Marketplace”, said Dr. Gauri Naik, Founder & Chief Executive Officer, OptraHEALTH. “This collaboration will dramatically enhance our reach in conversational AI services offered in the genetic health industry,” she added further.

“Azure helps OptraHEALTH deliver solutions that enable customers to focus more on their patients and less on managing servers,” said David Houlding MSc CISSP CIPP, Director Healthcare Experiences, Cloud + AI at Microsoft Corp. “The GeneFAX™ solution addresses a variety of issues related to the healthcare industry and enables customers to take advantage of the flexibility and enterprise-grade reliability Azure provides.”

Azure Marketplace helps connect companies seeking innovative, cloud-based solutions with partners who have developed solutions that are ready to use. The availability of GeneFAX™ Pro on Azure Marketplace shall help customers to use genetic information on the go.

To read the full coverage, please click link:https://finance.yahoo.com/news/optrahealth-collaborates-microsoft-azure-serve-165000627.html

GeneFAX™ Pro is an AI-powered HIPAA compliant, knowledge platform for genetic health with BOT interfaces and has three modules: ChatBOT, KnowledgeBOT and QuizBOT. This new-gen AI platform is suitable for educating patients, qualifying their interest in various genetic tests, patient consenting, family triaging and pre-test counseling. “KnowledgeBOT” is a compilation of more than 450,000 Q&As pertaining to Genomics and Genetic Testing. GeneFAX™ has Natural Language Processing (NLP) framework to interpret and query GeneFAX™ knowledgebase using 65 million ontological records pertaining to diseases, drugs, biological entities, chemicals, clinical ontologies, etc. GeneFAX™ “QuizBOT” is one of the first AI tools to educate and assess pre-test readiness of any patient in compliance with ACOG, NCCN guidelines in a conversational way using Quiz format.

GeneFAX™ “CounselorConnect™” provides easy connectivity with 75+ telegenetic counselors to get questions answered in real-time. GeneFAX™ caters to a number of genetics panel such as Non-invasive Prenatal Testing (NIPT), Carrier Screening, Hereditary Cancer Screening, Newborn Screening, just to name a few. GeneFAX™ application’s presence in Azure Marketplace will allow customers to benefit from access to information of such genetics panel, for example, anytime and anywhere.

“There are more than 25 million genetic tests conducted every year – and that number is doubling yearly. While there are only 10 genetic counselors per million population. To avoid long waits to speak with human counselors, patients are turning to random online searches to get questions answered, which only results in more confusion for the obvious reasons. Physicians are also looking for ways to educate patients on appropriate genetic tests. OptraHEALTH has invented GeneFAX™ to address this dilemma for patients as well as physicians. We are proud to be a market leader for “AI in Genetic Health” and look forward to increasing our reach using Azure Marketplace”, said Dr. Gauri Naik, Founder & Chief Executive Officer, OptraHEALTH. “This collaboration will dramatically enhance our reach in conversational AI services offered in the genetic health industry,” she added further.

“Azure helps OptraHEALTH deliver solutions that enable customers to focus more on their patients and less on managing servers,” said David Houlding MSc CISSP CIPP, Director Healthcare Experiences, Cloud + AI at Microsoft Corp. “The GeneFAX™ solution addresses a variety of issues related to the healthcare industry and enables customers to take advantage of the flexibility and enterprise-grade reliability Azure provides.”

Azure Marketplace helps connect companies seeking innovative, cloud-based solutions with partners who have developed solutions that are ready to use. The availability of GeneFAX™ Pro on Azure Marketplace shall help customers to use genetic information on the go.

Lorem ipsum

Lorem ipsum

Lorem ipsum

Visit Optra team at booth #610 to hear about the latest developments at OptraHEALTH. Talk to our genetics experts to learn about how GeneFAX™ can help in genetic counseling, pre and post-test education, patient triaging, family history generation and much more.

Experience a first-hand demo of ScreeningBOT™, KnowldegeBOT™, QuizBOT™, PhysicianBOT™, PedigreeBOT™ and CounselorConnect® applications and learn the various advantages of GeneFAX™ for your organization.

GeneFAX™ is available as a ChatBOT, VoiceBOT and iOS, and Android mobile app and is fully managed from admin interfaces.

Visit us at booth 610 for GeneFAX™ demo or email us at info@genefax.ai to arrange a demo.

Event details

Venue : Henry B. González Convention Center | San Antonio ,
Dates : March 17-21, 2020 | Exhibit Dates March 18-20
Booth : #610

As a result of the telegenetics partnership consumers on the GeneFAX™ Counselor Connect scheduling platform will be able to reach InformedDNA counselors online to ask questions about genetic and prenatal testing, enhancing the artificial intelligence-driven GeneFAX™ chatbot model offered by San Jose, California-based OptraHealth.

Notably, the GeneFAX™ system allows consumers and healthcare providers to query genetic data via a chatbot, mobile application, and voice assistants like Amazon's Alexa, Microsoft's Cortana, and Google Home.

"I strongly believe that the combination of GeneFax's AI technology and expert genetic counseling services of InformedDNA will extend the reach of genetic testing and engage users meaningfully," OptraHealth Founder and CEO Gauri Naik said in a statement. "It will also empower users to get more out of genetic testing in order to take control of their health."

"Partnering with OptraHealth opens yet another avenue to help patients, providers, labs, and payors better understand the genetic landscape, including testing and treatment considerations," Amber Trived, chief innovation officer of St. Petersburg, Florida-based InformedDNA, said. "Now, these audiences will have even more resources at their fingertips to help navigate the complexities related to genetic testing."

InformedDNA already provides counseling and management services to the likes of Coriell Institute for Medical Research, WIRB-Copernicus Group, and AIM Specialty Health to support drug development for precision medicine and to help payors manage appropriate genetic testing utilization.

To read the full coverage, please click the Genomeweb link: https://www.genomeweb.com/informatics/optrahealth-informeddna-partner-remote-genetic-counseling

San Jose, Calif. & St. Petersburg, FL: OptraHEALTH^®, creators of GeneFAX™, the conversational AI platform trained on genetics, and InformedDNA^®, nation's largest independent provider of genetics experts, today announced that they will partner  to offer access to InformedDNA’s board-certified genetic counselors through GeneFAX’s AI-enabled CounselorConnect platform.

GeneFAX Enterprise is a cloud service that empowers organizations to build and deploy AI-powered virtual assistants and chatbots that can be used to enhance their processes, patient engagements and reduce costs. InformedDNA was the first telegenetic service provider in the U.S. and now employs the nation’s largest, most experienced, full-time staff of genetic counselors.

GeneFAX CounselorConnect™ allows patients to schedule a genetic counseling appointment with a board-certified genetic counselor at their convenience. Patients may discuss about their families’ or their own genetic health and ask questions related to pre-test and post-test genetic testing, prenatal testing or any cancer-related genetic testing. GeneFAX’s CounselorConnect will enable GeneFAX™ users to access InformedDNA’s board-certified genetic counselors to connect remotely and obtain accurate answers to their questions and reach out to them for further steps on top of its AI powered e-counseling.

"We are committed towards providing accurate genetic information to the patients through GeneFAX™ and this partnership with InformedDNA will definitely help us in keeping our commitment. I strongly believe that the combination of GeneFAX’s AI technology and expert genetic counseling services of InformedDNA will extend the reach of genetic testing and engage users meaningfully", said Dr. Gauri Naik, Founder & Chief Executive Officer, OptraHEALTH. She further added, “It will also empower users to get more out of genetic testing in order to take control of their health."

“Since its creation, InformedDNA’s upmost mission has been to broaden access to genetic expertise and information. Partnering with OptraHEALTH opens yet another avenue to help patients, providers, labs and payers better understand the genetic landscape, including testing and treatment considerations,” said Amber Trivedi, M.S., CGC, Chief Innovation Officer for InformedDNA. “Now, these audiences will have even more resources at their fingertips to help navigate the complexities related to genetic testing.”

San Jose, CA, and St. Petersburg, FL, November 5th, 2019: OptraHEALTH^®, creators of GeneFAX™, the conversational AI platform trained on genetics, and InformedDNA^®, nation's largest independent provider of genetics experts, today announced that they will partner  to offer access to InformedDNA’s board-certified genetic counselors through GeneFAX’s AI-enabled CounselorConnect platform.

GeneFAX, a flagship product of OptraHEALTH, is an AI-powered knowledge platform for genetic health with bot interfaces. The GeneFAX™ platform includes a Digital Genetic Assistant trained on genetics knowledge to aid genetics labs/providers/payers in consenting, triaging, pre-test counseling and post-test counseling processes. GeneFAX™ Enterprise is a cloud service that empowers organizations to build and deploy, AI-powered virtual assistants and chatbots that can be used to enhance their processes, patient engagements and reduce costs.

InformedDNA was the first telegenetic service provider in the U.S. and now employs the nation’s largest, most experienced, full-time staff of genetic counselors. Covered specialties include: cancer, cardiac, neuro, ocular, reproductive, and pediatric genetics; pharmacogenomics; whole genome/exome sequencing; and, direct-to-consumer genetic test results consultation. Since InformedDNA is lab-independent, there are no conflicts of interest with its genetic counselors advising ordering providers and patients on the most appropriate use of genetic tests and their results.

GeneFAX CounselorConnect™ allows patients to schedule a genetic counseling appointment with a board-certified genetic counselor at their convenience. Patients may discuss about their families’ or their own genetic health and ask questions related to pre-test and post-test genetic testing, prenatal testing or any cancer-related genetic testing. GeneFAX’s CounselorConnect will enable GeneFAX™ users to access InformedDNA’s board-certified genetic counselors to connect remotely and obtain accurate answers to their questions and reach out to them for further steps on top of its AI powered e-counseling.

“We are committed towards providing accurate genetic information to the patients through GeneFAX™ and this partnership with InformedDNA will definitely help us in keeping our commitment. I strongly believe that the combination of GeneFAX’s AI technology and expert genetic counseling services of InformedDNA will extend the reach of genetic testing and engage users meaningfully”, said Dr. Gauri Naik, Founder & Chief Executive Officer, OptraHEALTH. She further added, “It will also empower users to get more out of genetic testing in order to take control of their health.”

“Since its creation, InformedDNA’s upmost mission has been to broaden access to genetic expertise and information. Partnering with OptraHEALTH opens yet another avenue to help patients, providers, labs and payers better understand the genetic landscape, including testing and treatment considerations,” said Amber Trivedi, M.S., CGC, Chief Innovation Officer for InformedDNA. “Now, these audiences will have even more resources at their fingertips to help navigate the complexities related to genetic testing.”

Come and join us to find out what’s shaping the future of genetics and genomics! Visit Optra team at booth #1016 to hear about the latest developments at Optra Health. Talk to our Genetic expert Dr. Ashwin to learn about how GeneFAX™ Enterprise solution can help in Genetic E-counselling. And how it can be used as Genetic testing Guidelines ,consent, Followup BOT, eduaction tool for patient and provider.

Event details

Venue : Washington State Convention Center | Seattle ,
Dates : April 3-5, 2019
Booth : #1016

Lorem ipsum

Lorem ipsum

Lorem ipsum

The recognition is given annually to a woman entrepreneur whose vision and pioneering spirit has led to significant achievements in corporate responsibility practices over the course of her career. The award will be presented on February 22nd during 9th Women Entrepreneurs Conference at The Park Hotel, New Delhi.

Dr. Naik founded OptraHEALTH in the year 2014 based on the idea that AI can help in providing Genetic Counseling to everybody at very low cost. OptraHEALTH’s latest product ‘GeneFAXTM: Digital Genetic Companion’, is a Chatbot for Genetics which guides individuals through the preliminary steps of their genetic test. GeneFAXTM can answer basic genetics queries as well as help the users to interpret their DNA test report. Dr. Gauri led OptraHEALTH has achieved the highest level of appreciation and success in genetic industry. She is a biotechnologist by profession, with commercial research and entrepreneurial background. She has extensive experience working in the genetics, cytology, microbiology, molecular biology, medical imaging and bioinformatics field and has 11 US patents published to her credit.

“I am deeply humbled and honored by this recognition. This award is a testimony that OptraHEALTH is helping millions of people all over the world with our conversational AI tools to know their genetic history. This is a recognition for our entire OptraHEALTH team to be persistent and always pursuing excellence in improving lives of consumers through new-age technology”, said Dr. Gauri Naik. She added by saying, “Although we believe that a conversational AI can never replace a Human Genetic Counselor, it can certainly help people to prepare for pre-test counseling and post-test counseling sessions.”

Dr. Naik was selected from a group of finalists by a panel of independent judges comprised of previous Responsible CEO Award winners. Finalists for the award were nominated by DMA leadership team who are elected members of DMA community, based on a nominee's achievements spanning a career in corporate responsibility practices; including employee relations, environmental impact and sustainability, human rights and philanthropy.

"Our entire community of healthcare professionals applauds Dr. Gauri Naik’s efforts and for leading by example throughout her career – driving innovation and creating a culture of sustainability and purpose for employees, customers and the communities where OptraHEALTH’s GeneFAXTM operates”, said Abhi Gholap, co-founder of Optra Health.

Pune, 1st March : OptraHEALTH, a leading data-driven intelligence company announced the availability of GeneFAX™, a conversation AI-powered app for genetics and genetic testing on Android and is available in the Google Play Store. GeneFAX™ empowers consumers to ask any question about genetics in a conversational manner and receive answers in a simple and easy to understand manner

“Genetic testing is advancing at enormous speed, with tens of thousands of new findings published every year, and millions of additional tests performed. According to a research, there is only one genetic counselor per 75000 people. The idea behind developing GeneFAX™ is to bridge this gap by providing validated accurate information to consumers and acting as a technology partner for the genomics industry, said Optra's spokeperson in a press conference.

We are taking the first step to offer this AI-based chatbot & voicebot for consumers, genetic counselors, and healthcare organizations and we believe this will be a game changer in the field of digital genetic counseling. OptraHEALTH has already launched the iOS version GeneFAX™ and received a tremendous response. And now with GeneFAX™ available on Android, we are able to reach an even greater audience. This will also be a significant step in providing better access to genetic information to all.” Said Dr. Ashwin Kotwaliwale MD Ph.D., Medical Director of OptraHEALTH. He added by saying, “Although we believe that a conversational AI can never replace a human genetic counselor, it can certainly help consumers, patients and families to prepare for both pre and post-test counseling.”

By design, GeneFAX™ has many features that make the process of gathering genetics information quick and easy. GeneFAX™ provides contextually relevant user guidance yet allowing users to ask any question in spoken English at any time. This functionality of composing a question in your own language has increased GeneFAX™ adoption. Now by harnessing the power of Android, consumers can interact with even more features such as audio and multimedia content. Consumers also receive a transcript of their chat with GeneFAX™.

GeneFAX™ benefits organization by providing more productivity to genetic counselors and GeneFAX™ for Enterprise allows enterprise users to take complete control of the contents and personalize the contents for their patients and families all with a click of a button. “The convergence of artificial intelligence, conversational technologies, and ever-increasing availability of genetic data is having a transformative effect on how research and clinical results are delivered and communicated,” said Dr. Gauri Naik, Co-founder, and CEO of OptraHEALTH. “The possibilities of using GeneFAX™ in combination with extensive public and private datasets, will advance research and improve consumer experience. We look forward to making GeneFAX™ accessible to genetic testing organizations that are interested in providing more value through a personalized, digital approach.”

Optra Health today announced the introduction of a revolutionary new business solution—GeneFAX™. GeneFAX™ harnesses vast stores of genetic data locked away in corporate and public data silos, combines it with leading edge artificial intelligence and conversational technologies like Amazon Alexa to give genetic testing organizations the ability to offer a ‘round-the-clock’ personalized and engaging service to their consumers, and more effective tools for their genetic counselors and scientists.

Optra Health introduce GeneFAX™ at the HL7 Genomics Conference in Washington D.C., where Mr. Abhi Gholap, Co-founder and Executive Chairman, discussed ‘The Intersection of Artificial Intelligence and Healthcare as it relates to Innovation’.

GeneFAX™ Technology and Amazon Alexa

Optra Health today announced the introduction of a revolutionary new business solution—GeneFAX™. GeneFAX™ harnesses vast stores of genetic data locked away in corporate and public data silos, combines it with leading edge artificial intelligence and conversational technologies like Amazon Alexa to give genetic testing organizations the ability to offer a ‘round-the-clock’ personalized and engaging service to their consumers, and more effective tools for their genetic counselors and scientists.

Optra Health introduce GeneFAX™ at the HL7 Genomics Conference in Washington D.C., where Mr. Abhi Gholap, Co-founder and Executive Chairman, discussed ‘The Intersection of Artificial Intelligence and Healthcare as it relates to Innovation’.

GeneFAX™ Technology and Amazon Alexa

Consumers have more access to data than ever before which presents potential risks in interpreting complex and often ambiguous information. Genetic Counseling can clear up this ambiguity but may not be readily available when the consumer needs it. GeneFAX, powered by iPhronesis, utilizes Amazon’s Voice Recognition (VR) capabilities for conversation, along with a rich Ontological Library of over 65 million unique life sciences and healthcare concepts and extensive Natural Language Understanding (NLU) and Deep Machine Learning (ML) capabilities provided by the iPhronesis platform to communicate results in a comprehensive and compassionate manner. Consumers can engage in a conversation with GeneFAX™; asking questions and getting detailed answers about their results.

GeneFAX™ is not limited to consumers—genetic testing organizations can deploy GeneFAX™ to their genetic counselors engaged in family screening, allowing them to access and compare reports across an entire family and keep up-to-speed with the latest research – ensuring counseling sessions can be more effective. Additionally, GeneFAX™ can be used by bioinformaticians and scientists involved in data analysis to conversationally interrogate raw data and gather more evidence prior to report generation.

“The convergence of artificial intelligence, conversational technologies like Alexa, and an ever-increasing availability of data is having a transformative effect on how research and clinical results are delivered and communicated,” said Co-founder and CEO Gauri Naik. “The possibilities of using GeneFAX™ and Ai platforms like iPhronesis™ in combination with extensive public and private data sets, will advance research and improve the consumer experience. We look forward to making GeneFAX™ accessible to genetic testing organizations that are interested in providing more value through a personalized, digital approach.”

GeneFAX™ is not limited to consumers—genetic testing organizations can deploy GeneFAX™ to their genetic counselors engaged in family screening, allowing them to access and compare reports across an entire family and keep up-to-speed with the latest research – ensuring counseling sessions can be more effective. Additionally, GeneFAX™ can be used by bioinformaticians and scientists involved in data analysis to conversationally interrogate raw data and gather more evidence prior to report generation.

“The convergence of artificial intelligence, conversational technologies like Alexa, and an ever-increasing availability of data is having a transformative effect on how research and clinical results are delivered and communicated,” said Co-founder and CEO Gauri Naik. “The possibilities of using GeneFAX™ and Ai platforms like iPhronesis™ in combination with extensive public and private data sets, will advance research and improve the consumer experience. We look forward to making GeneFAX™ accessible to genetic testing organizations that are interested in providing more value through a personalized, digital approach.”

The OptraGURU platform combines the AI tech of iPhronesis with the language capabilities of Amazon’s Alexa. Users can speak directly to OptraGURU to navigate through extensive genomic datasets or receive personalized insights.

“The convergence of artificial intelligence, conversational technologies like Alexa, and an ever-increasing availability of data is having a transformative effect on how research and clinical results are delivered and communicated,” Optra Health cofounder and CEO Gauri Naik said in a statement. “The possibilities of using OptraGURU and AI platforms like iPhronesis in combination with extensive public and private data sets, will advance research and improve the consumer experience.”

At the consumer level, Optra’s platform looks to help users better understand genetic testing results ordered by a provider. By asking an Alexa device loaded with OptraGURU to access their report, consumers can listen to an understandable explanation of their genetic data and ask the system specific questions about their results.

Along with reducing consumers’ demand for interpretations from trained genetic counselors, the platform also offers these professionals some benefits as well. OptraGURU primarily acts as a research resource, but can also load multiple genetic tests for easy side-by-side comparisons. Further, the technology can also assist genetic researchers by navigating and analyzing variant call format (VCF) files through natural language voice prompts.

Optra Health is debuting OptraGURU this weekend at the HL7 Genomics Conference in Washington D.C.

“We look forward to making OptraGURU accessible to genetic testing organizations that are interested in providing more value through a personalized, digital approach,” Naik said.

To read the full coverage, please click link:https://directprimarycare.com/2018/09/01/optra-health-launches-alexa-powered-ai-genomics-platform/

SUNNYVALE, Calif., Mar 23, 2017 (BUSINESS WIRE): OptraHEALTH^® today announced at the ACMG Clinical Genetics Annual Meeting the launch of its computational platform iPhronesis™ Knowledge Automation for Clinical Genomics using proprietary advanced natural language processing (NLP) algorithms and deep machine learning unique to the marketplace, as well as iPhronesis™ Cognitive Workbench “ICW” for automating literature and data review. The iPhronesis platform enables rapid data curation, ACMG-guided variant classification and clinical reporting.

iPhronesis Software and Why It Is aGame-changer

iPhronesis was developed to help curators, bioinformaticians and lab directors automate the laborious process of reporting on NGS data, when under increasingly tight deadlines for critical health judgements. The easy-to-use iPhronesis platform utilizes proprietary advanced Natural Language Processing (NLP) algorithms to leverage human language and its context to find hidden relationships in data. These hidden relationships are the basis for pathogenicity calls in variant classification, quality assessment and literature review for data curation, and ultimately the judgement calls lab directors make every day when approving clinical reports. No other upstream or downstream genomics software offers advanced NLP technology to aid in contextual data analysis and discovery.

>Deep Machine Learning trains the system per use to build evidence and confidence for variant classification, and includes an ontology database of >200 million ontologies and growing. Built-in ACMG guidelines provide an efficient and reliable process to classify variants and report to clinicians with confidence. Request a demo now at info@iphronesis.com

Platform Modules

iPhronesis includes robust data connectors to public databases like ClinVar and connects to repositories such as PubMed and OMIM. Users can connect to proprietary internal databases while also accessing online content for curation and knowledgebase creation. Bioinformaticians can easily implement pre-loaded workflows or customize their own using drag and drop functionality. Advanced D3 visualizationsand analytics provide lab directors and bioinformaticians cutting edge tools to visually display results and customize information to their specific needs. An intuitive user interface and simple workflow make adopting the software fast and efficient.

Gauri Naik, Ph.D., Chief Executive Officer and Co-Founder of Optra Health said, “Our aim is to provide a scalable, easy-to-use platform for all genomic and genetics professionals. The data burden problem is real and the ability to extract high quality, reliable data is becoming increasingly difficult as time goes on. Lab directors should feel 100% confident that the information they are relying on is actionable and evidence-based. iPhronesis will be the one-stop-shop to provide the highest quality data as it becomes available in real-time.”

HealthFAX™ is brought to you by OptraHEALTH a world leader in genetic health ChatBot. The ChatBot is free to access.

“The COVID-19 pandemic has caused significant loss of life, chaos and panic. This is our contribution to support the community during this difficult time of global crisis. We have developed COVID-19 ChatBot to keep people informed and safe. We will continue to do everything we can to help protect the vulnerable and help end this pandemic.” said Dr. Gauri Naik, Co-Founder & Chief Executive Officer, OptraHEALTH.

OptraHealth’s AI framework has over 50,000 frequently asked questions about COVID-19. It has over 65 million ontologies to interpret the questions asked by patients using free text. Through this ChatBot, one can also live chat and live call with the physicians. OptraHealth's AI platform connects with organization’s EMR records, clinical notes and medical literature to derive meaningful insights during this pandemic using all the data points gathered conversationally through ChatBot.

HealthFAX™ is brought to you by OptraHEALTH a world leader in genetic health ChatBot. The ChatBot is free to access.

“The COVID-19 pandemic has caused significant loss of life, chaos and panic. This is our contribution to support the community during this difficult time of global crisis. We have developed COVID-19 ChatBot to keep people informed and safe. We will continue to do everything we can to help protect the vulnerable and help end this pandemic.” said Dr. Gauri Naik, Co-Founder & Chief Executive Officer, OptraHEALTH.

OptraHealth’s AI framework has over 50,000 frequently asked questions about COVID-19. It has over 65 million ontologies to interpret the questions asked by patients using free text. Through this ChatBot, one can also live chat and live call with the physicians. OptraHealth's AI platform connects with organization’s EMR records, clinical notes and medical literature to derive meaningful insights during this pandemic using all the data points gathered conversationally through ChatBot.

HealthFAX™ is brought to you by OptraHEALTH a world leader in genetic health ChatBot. The ChatBot is free to access.

“The COVID-19 pandemic has caused significant loss of life, chaos and panic. This is our contribution to support the community during this difficult time of global crisis. We have developed COVID-19 ChatBot to keep people informed and safe. We will continue to do everything we can to help protect the vulnerable and help end this pandemic.” said Dr. Gauri Naik, Co-Founder & Chief Executive Officer, OptraHEALTH.

OptraHealth’s AI framework has over 50,000 frequently asked questions about COVID-19. It has over 65 million ontologies to interpret the questions asked by patients using free text. Through this ChatBot, one can also live chat and live call with the physicians. OptraHealth's AI platform connects with organization’s EMR records, clinical notes and medical literature to derive meaningful insights during this pandemic using all the data points gathered conversationally through ChatBot.

HealthFAX™ is brought to you by OptraHEALTH a world leader in genetic health ChatBot. The ChatBot is free to access.

“The COVID-19 pandemic has caused significant loss of life, chaos and panic. This is our contribution to support the community during this difficult time of global crisis. We have developed COVID-19 ChatBot to keep people informed and safe. We will continue to do everything we can to help protect the vulnerable and help end this pandemic.” said Dr. Gauri Naik, Co-Founder & Chief Executive Officer, OptraHEALTH.

OptraHealth’s AI framework has over 50,000 frequently asked questions about COVID-19. It has over 65 million ontologies to interpret the questions asked by patients using free text. Through this ChatBot, one can also live chat and live call with the physicians. OptraHealth's AI platform connects with organization’s EMR records, clinical notes and medical literature to derive meaningful insights during this pandemic using all the data points gathered conversationally through ChatBot.

HealthFAX™ is brought to you by OptraHEALTH a world leader in genetic health ChatBot. The ChatBot is free to access.

“The COVID-19 pandemic has caused significant loss of life, chaos and panic. This is our contribution to support the community during this difficult time of global crisis. We have developed COVID-19 ChatBot to keep people informed and safe. We will continue to do everything we can to help protect the vulnerable and help end this pandemic.” said Dr. Gauri Naik, Co-Founder & Chief Executive Officer, OptraHEALTH.

OptraHealth’s AI framework has over 50,000 frequently asked questions about COVID-19. It has over 65 million ontologies to interpret the questions asked by patients using free text. Through this ChatBot, one can also live chat and live call with the physicians. OptraHealth's AI platform connects with organization’s EMR records, clinical notes and medical literature to derive meaningful insights during this pandemic using all the data points gathered conversationally through ChatBot.

HealthFAX™ is brought to you by OptraHEALTH a world leader in genetic health ChatBot. The ChatBot is free to access.

“The COVID-19 pandemic has caused significant loss of life, chaos and panic. This is our contribution to support the community during this difficult time of global crisis. We have developed COVID-19 ChatBot to keep people informed and safe. We will continue to do everything we can to help protect the vulnerable and help end this pandemic.” said Dr. Gauri Naik, Co-Founder & Chief Executive Officer, OptraHEALTH.

OptraHealth’s AI framework has over 50,000 frequently asked questions about COVID-19. It has over 65 million ontologies to interpret the questions asked by patients using free text. Through this ChatBot, one can also live chat and live call with the physicians. OptraHealth's AI platform connects with organization’s EMR records, clinical notes and medical literature to derive meaningful insights during this pandemic using all the data points gathered conversationally through ChatBot.